Kessler Paul D. 4
4 · NABI BIOPHARMACEUTICALS · Filed May 19, 2010
Insider Transaction Report
Form 4
Kessler Paul D.
SVP Clinical, Med. & Reg.; CMO
Transactions
- Sale
Common Stock
2010-05-17$5.71/sh−700$3,994→ 107,147 total - Sale
Common Stock
2010-05-17$5.68/sh−300$1,704→ 112,952 total - Sale
Common Stock
2010-05-17$5.70/sh−1,000$5,695→ 111,052 total - Sale
Common Stock
2010-05-17$5.70/sh−3,205$18,269→ 107,847 total - Sale
Common Stock
2010-05-17$5.68/sh−50$284→ 112,902 total - Sale
Common Stock
2010-05-17$5.69/sh−850$4,837→ 112,052 total - Sale
Common Stock
2010-05-17$5.71/sh−3,592$20,510→ 103,555 total - Sale
Common Stock
2010-05-17$5.71/sh−100$572→ 103,455 total - Sale
Common Stock
2010-05-17$5.72/sh−1,900$10,868→ 101,555 total - Sale
Common Stock
2010-05-17$5.72/sh−100$573→ 101,455 total - Sale
Common Stock
2010-05-17$5.73/sh−1,400$8,022→ 100,055 total - Sale
Common Stock
2010-05-17$5.74/sh−1,003$5,757→ 99,052 total - Sale
Common Stock
2010-05-17$5.75/sh−600$3,450→ 98,452 total - Sale
Common Stock
2010-05-17$5.76/sh−200$1,152→ 98,252 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.